Related Experiment Video
Updated: Apr 18, 2026
09:12
High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
Published on: June 10, 2025
1.5K
Aflibercept: an update on recent milestones achieved
1Retina Vitreous Division, Casey Eye Institute, Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
Drugs of Today (Barcelona, Spain : 1998)
|January 15, 2015
Summary
Intravitreal anti-VEGF medications, including aflibercept, have transformed retinal disease treatment. These therapies significantly improve vision in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME).
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Background:
- Intravitreal anti-VEGF agents have revolutionized retinal disease management over the past decade.
- Pegaptanib, ranibizumab, and bevacizumab improved visual acuity in age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Purpose of the Study:
- To evaluate the role and effectiveness of aflibercept, a newer anti-VEGF drug, in treating retinal vascular diseases.
- To compare aflibercept's efficacy with existing treatments like ranibizumab and bevacizumab.
Main Methods:
- Clinical trials assessing visual acuity and treatment outcomes.
- Pharmacological analysis of aflibercept's mechanism of action, targeting all VEGF isoforms and placental growth factor.
Main Results:
- Aflibercept demonstrated comparable effectiveness to existing anti-VEGF therapies in clinical trials.
- Aflibercept is now a key treatment option for neovascular AMD.
- Aflibercept is emerging as a significant therapeutic choice for DME and RVO.
Conclusions:
- Aflibercept represents a valuable addition to the therapeutic arsenal for retinal vascular diseases.
- The continued development of anti-VEGF therapies offers improved visual outcomes for patients with AMD, DME, and RVO.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
336
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
336
01:28Preclinical Development: Overview
6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
02:56Treatment Resistent Cancers
1.5K
1.5K
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:57Targeted Cancer Therapies
1.8K
1.8K
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K